Analyst Profile

Followed by 347 followers
.
Debjit Chattopadhyay

Debjit Chattopadhyay

Guggenheim
Wall Street Analyst
#235 out of 8,141 Wall Street Analysts
#420 out of 24,284 experts

Success Rate

49%
181 out of 372 transactions made a profit

Average Return

+19.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Debjit Chattopadhyay's trades since 2014 and holding each position for 1 Year would result in 48.66% of your transactions generating a profit, with an average return of 19.1% per rating.

Stock Rating Distribution

828Ratings
90.82% Buy
8.82% Hold
0.36% Sell
Distribution of Debjit Chattopadhyay's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Mersana Therapeutics
(MRSN)
Rating:Buy
Date:Nov 07, 2019 - Nov 07, 2020
Return:+800.00%
The most profitable rating made by Debjit Chattopadhyay

Debjit Chattopadhyay's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
~RNA
Prosensa Holding
Nov 25, 2014
Hold
Downgraded
6Ratings
0.00%
HPTX
Hyperion Therapeutics
Mar 30, 2015
Hold
Downgraded
8Ratings
0.00%
Fresh Tracks Therapeutics
Jun 23, 2015
Hold
Downgraded
$1.70
(-10.53% Downside)
3Ratings
0.00%
CTI BioPharma
Aug 11, 2015
Buy
Reiterated
$4.50
(-25.25% Downside)
10Ratings
0.00%
Arcturus Therapeutics
Aug 14, 2015
Buy
Reiterated
$16.00
(-13.23% Downside)
13Ratings
0.00%
Aspira Women's Health
Aug 16, 2015
Buy
Reiterated
$4.00
(1004.97% Upside)
7Ratings
0.00%
TRACON Pharmaceuticals
Oct 07, 2015
Buy
Reiterated
$18.00
(1096.01% Upside)
4Ratings
0.00%
PTC Therapeutics
Oct 16, 2015
Hold
Reiterated
$63.00
(51.84% Upside)
19Ratings
0.00%
NeoGenomics
Oct 26, 2015
Buy
Initiated
$10.00
(-10.79% Downside)
23Ratings
0.00%
SBBP
Strongbridge Biopharma
Apr 18, 2016
Buy
Reiterated
1Ratings
0.00%
List of latest recommendations made by Debjit Chattopadhyay. Click to expand and see Debjit Chattopadhyay's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >